Waddell & Reed Financial’s AbbVie ABBV Stock Holding History

Waddell & Reed Financial’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-245,971	Closed	-$22.7M	–	491
2018 Q4	$22.7M	Sell	245,971 -33,459	-12%	-$2.94M	0.06%	312
2018 Q3	$26.4M	Sell	279,430 -118,266	-30%	-$11.2M	0.06%	301
2018 Q2	$36.8M	Sell	397,696 -55,614	-12%	-$5.43M	0.09%	261
2018 Q1	$42.9M	Buy	453,310 +380,220	+520%	+$41.8M	0.1%	237
2017 Q4	$7.07M	Sell	73,090 -22,762	-24%	-$2.15M	0.02%	455
2017 Q3	$8.52M	Sell	95,852 -24,048	-20%	-$1.83M	0.02%	434
2017 Q2	$8.69M	Buy	+119,900	New	+$8.06M	0.02%	444
2015 Q4	–	Sell	-446,260	Closed	-$24.3M	–	618
2015 Q3	$24.3M	Buy	446,260 +66,360	+17%	+$4.32M	0.04%	291
2015 Q2	$25.5M	Buy	+379,900	New	+$24.8M	0.04%	306
2015 Q1	–	Sell	-85,349	Closed	-$5.58M	–	562
2014 Q4	$5.58M	Buy	85,349 +35,671	+72%	+$2.25M	0.01%	477
2014 Q3	$2.87M	Buy	+49,678	New	+$2.76M	﹤0.01%	515

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Waddell & Reed Financial's ABBV Position: Q1 2019 in Review

Waddell & Reed Financial sold out of AbbVie (ABBV) in Q1 2019, closing a stake of 245,971 shares — an estimated $22.7M sold.

Waddell & Reed Financial first reported a position in ABBV in Q3 2014 and held it in 11 quarters. The position peaked at $42.9M in Q1 2018. 2,033 funds tracked by Wall St. Rank hold ABBV as of Q1 2019.

Waddell & Reed Financial reported no remaining AbbVie position as of Q1 2019 after selling out during the quarter.
Waddell & Reed Financial sold 245,971 AbbVie shares in Q1 2019, an estimated $22.7M.
Waddell & Reed Financial first reported a position in AbbVie in Q3 2014 and held it in 11 quarters.
Waddell & Reed Financial's AbbVie position peaked at $42.9M in Q1 2018.
2,033 funds tracked by Wall St. Rank held AbbVie as of Q1 2019.

Based on Waddell & Reed Financial's 13F filing for Q1 2019, filed 15 May 2019.